Poolbeg Pharma Expands Global IP Position with Canadian Patent for POLB 001 in CRS
As reported on PharmaTimes, Poolbeg Pharma has secured a Canadian patent protecting the use of p38 MAPK inhibitors, including its lead candidate POLB 001, for preventing cytokine release syndrome (CRS) associated…